Announcements Trials
Browse Landscape

Phase

Phase 2 68Phase 1 10Phase 1/2 8Phase NA 4Phase 3 2Phase 2/3 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1NSCLC 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Axitinib × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown
20 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡